In June 2026, CARsgen Therapeutics announced that its CLDN18.2-targeting autologous CAR-T product, satricabtagene autoleucel (Saikaize®), received conditional approval from the NMPA for advanced gastric cancer patients who have failed at least second-line therapy, priced at RMB 990,000 per dose (approximately USD 137,500). This is the world’s first solid tumor CAR-T product approved for market; three days after approval it entered commercial clinical use at Shanghai Zhongshan Hospital, marking the formal advance of cell therapy from hematological tumors into the solid tumor battlefield.
The Value of “the First”: The Clinical Significance of CAR-T Therapy for Solid Tumors
The Dilemma of Targeted Therapy — The Current State of Advanced Gastric Cancer Treatment
Gastric cancer is the fifth most common cancer worldwide. According to IARC 2022 data, China sees approximately 480,000 new gastric cancer cases each year, accounting for nearly half of the global total, with about 70% already at an advanced stage at initial diagnosis. Among all gastric cancer patients, the CLDN18.2 positivity rate is about 50%–70%, meaning roughly 250,000 to 350,000 new cases carry this target — a patient population large enough to support a complete commercial rationale.
Although the treatment ladder for advanced gastric cancer has improved somewhat, the overall prognosis remains unfavorable:
| Line of therapy | Standard regimen | mOS | ORR |
| First line | PD-1 inhibitor + chemotherapy (XELOX/SOX) | ~14 months | 40%–55% |
| Second line | Ramucirumab + paclitaxel | ~10 months | 25%–35% |
| Third line and beyond | Apatinib / TAS-102 / Nivolumab | 5–7 months | 5%–10% |
The “precision” path of targeted therapy for gastric cancer has not been smooth. HER2-positive cases account for only 15%–20%, and the median time to resistance for the first-generation targeted drug trastuzumab is just 7–8 months; while ADC drugs have some activity, resistance develops rapidly and safety management is difficult. For the largest patient group — CLDN18.2-positive patients — there was previously no targeted regimen in the true sense; chemotherapy combined with immunotherapy remained “blind shooting without a visible target.”
CAR-T’s Technical Path — How It Differs from Existing Treatment Paradigms
The underlying logic of CAR-T is fundamentally different from all existing drugs: it does not rely on small molecules or antibodies to block signaling pathways, but instead engineers the patient’s own T cells so that they acquire the ability to recognize and kill tumor cells — “turning cells into a drug.”
From hematological tumors to solid tumors, CAR-T faces three biological barriers: first, an infiltration barrier — solid tumors are wrapped in dense stroma and fibrous tissue, making it difficult for T cells to penetrate; second, an immunosuppressive microenvironment — the tumor microenvironment suppresses T cell function by secreting factors such as TGF-β and IL-10; third, antigen heterogeneity — solid tumor cells express antigens unevenly, and cells with low or no expression can evade immune attack.
CARsgen’s technical breakthroughs are built around these three barriers. As a tight-junction protein, CLDN18.2 is expressed in normal tissue only on the basolateral side of the gastric mucosal epithelium, while it is abnormally overexpressed in tumors such as gastric and pancreatic cancer — this tissue-restricted expression reduces the risk of off-target toxicity. An optimized single-chain variable fragment (scFv) increases the binding affinity of the CAR molecule. “Armored CAR” technology, by co-expressing cytokines such as IL-7 and CCL19, enhances the infiltration capacity and persistence of T cells.
The Efficacy of Satricabtagene Autoleucel: A Breakthrough Improvement Over the Standard
In the pivotal clinical trials published to date, satricabtagene autoleucel’s improvement over standard third-line therapy is significant:
| Metric | Satricabtagene autoleucel (second line and beyond) | Standard third-line therapy | Fold improvement |
| Objective response rate (ORR) | >50% | 5%–10% | 5–10x |
| Median progression-free survival (mPFS) | ~6–7 months | 2–3 months | 2–3x |
| Median overall survival (mOS) | ~12–14 months | 5–7 months | ~2x |
| Disease control rate (DCR) | ~80% | 30%–40% | ~2x |
CAR-T has another important characteristic: a single administration with long-term benefit. After the cells expand in vivo and form memory T cells, they can continuously monitor for tumor recurrence over months or even years. For advanced-stage patients, this means not only fewer hospital visits but also an improvement in quality of survival.
A Hot Potato: The Commercialization Dilemma of Solid Tumor CAR-T
The Dilemma of Pricing Logic
On June 29, 2026, CARsgen Therapeutics officially announced the pricing of satricabtagene autoleucel — RMB 990,000 per dose (approximately USD 137,500), about 17% lower than Yescarta’s China pricing. But as the world’s first solid tumor CAR-T, its core contradiction is not resolved by pricing: a large patient pool but a relatively late line of therapy. The indications for hematological CAR-T are mostly relapsed/refractory leukemia or lymphoma, where the absolute number of patients is limited but willingness to pay is extremely high. For solid tumor CAR-T, although the potential beneficiary population is several times that of hematological tumors, the median survival of third-line gastric cancer patients is only 5–7 months, and some patients cannot even complete the 2–3 week waiting period for cell manufacturing.
Cost Structure: Why CAR-T Is Destined to Be Expensive
Unlike the “industrialized assembly line” of chemical drugs or monoclonal antibodies, autologous CAR-T is a personalized, custom-made product — “one drug per person”:
| Cost item | Share | Description |
| Lentiviral vector | 30%–40% | Extremely high GMP-grade production cost |
| Manufacturing | 20%–25% | Aseptic operations, QC testing, release standards |
| R&D amortization | 15%–20% | Allocation of upfront clinical investment |
| Commercialization expenses | 10%–15% | Academic promotion, logistics cold chain |
The lentiviral vector is the largest rigid cost item. According to industry estimates, the cost of GMP-grade vector is about RMB 10,000–100,000 per dose (approximately USD 1,400–13,900, depending on scale and purification process), and the manufacturing failure rate for autologous products is between 5% and 15%, further pushing up the effective cost. The long-term path to cost reduction lies in universal CAR-T — which could theoretically bring the per-dose cost down to 1/5 to 1/10 of that of autologous products, but the in vivo persistence and safety of universal products in solid tumors have not yet been validated, and commercialization is still at least 3–5 years away.
The challenge of China’s payment system is therefore all the more acute. CAR-T products already on the market are covered mainly through Huimin Bao (inclusive medical insurance) and high-end commercial health insurance, with reimbursement ratios mostly between 50% and 70% and subject to payout caps. At the RMB 990,000 price, even with commercial insurance coverage, the patient’s out-of-pocket portion remains RMB 300,000–500,000 (approximately USD 41,700–69,400), which is still a heavy burden for the vast majority of Chinese families.
Pipeline and Battlefield: CARsgen’s Line of Advance
Satricabtagene autoleucel is only the starting point of CARsgen’s solid tumor CAR-T strategy. In terms of pipeline layout, CARsgen is building a product matrix around two core targets, CLDN18.2 and BCMA:
| Indication | Target | Clinical stage | Market potential assessment |
| Gastric cancer (approved) | CLDN18.2 | Approved | Moderate |
| Pancreatic cancer | CLDN18.2 | Phase II (FDA + EMA orphan drug designation) | Relatively large |
| First-line gastric cancer | CLDN18.2 | Phase II | Very large |
| Multiple myeloma | BCMA | Approved (Zevor-cel) | Moderate |
Pancreatic cancer is considered the most explosive expansion direction (CLDN18.2 positivity rate 60%–80%, five-year survival rate below 10%); CARsgen has already obtained FDA and EMA orphan drug designations and is expected to submit a new indication application around 2028. Moving first-line gastric cancer treatment up the line would expand the patient pool by 3–5 times, but requires head-to-head comparison with the first-line standard regimen, with a trial cycle lasting as long as 3–5 years.
Global competitors are already accelerating their pursuit:
| Company | Core target | Leading indication | Clinical stage | Highlight |
| CARsgen Therapeutics | CLDN18.2 | Gastric cancer | Approved | Global frontrunner |
| Lion TCR | GPC3 | Liver cancer | Phase II | Obtained CDE confirmatory Phase II clinical approval in June 2026 |
| Gracell Biotech / AstraZeneca | GPC3 / CLDN18.2 | Liver cancer / Gastric cancer | Phase I/II | MNC endorsement |
| Unicar-Therapy | Multiple targets | Various solid tumors | Phase I | Dual-targeting CAR |
Lion TCR’s GPC3 mRNA CAR-T is the second solid tumor CAR-T project to enter the confirmatory stage after CARsgen; the GPC3 target’s coverage of liver cancer (about 370,000 new cases per year) is complementary to CLDN18.2’s coverage of gastric cancer. After Gracell Biotech was acquired by AstraZeneca in January 2024 for USD 1.2 billion, it gained the global clinical capabilities of an MNC (multinational corporation), meaning CARsgen’s first-mover window may be shorter than expected. From the target dimension, the two major targets CLDN18.2 (gastric + pancreatic + esophageal cancer) and GPC3 (liver cancer) together account for about 600,000–800,000 newly diagnosed accessible patients per year; if 3–5 targets advance simultaneously, an annual solid tumor CAR-T treatment population in the millions is not impossible.
Key Factors Affecting Commercialization Outcomes
Whether the solid tumor CAR-T field can deliver on market expectations depends on the interplay of the following core variables:
| Variable dimension | Upward driving force | Downward drag factor |
| Technology | Breakthroughs in universal CAR-T, declining CMC costs | TME resistance, antigen escape |
| Regulatory | Conditional approval pathway can be replicated | Safety signals leading to market withdrawal |
| Payment | Inclusion via medical insurance negotiation, expansion of commercial insurance | Pricing below expectations, insufficient willingness to pay |
| Competition | The “catfish effect” driving education and penetration | Homogenized involution, price wars |
On the technology side, universal CAR-T is the ultimate answer to cost reduction, but the lesson of Allogene’s clinical trial being suspended by the FDA in 2022 due to chromosomal abnormalities shows that there is still a long way to go before safety is validated. On the regulatory side, the CDE updated the “Technical Guidelines for Clinical Trials of Cell Therapy Products (Trial)” in 2025, with stricter requirements for confirmatory trials, and whether the conditional approval pathway will remain continuously open is still unknown. On the payment side, the 2025 national medical insurance negotiations did not include any CAR-T product, but multiple provinces and cities have incorporated them into inclusive commercial health insurance.
On balance, China’s solid tumor CAR-T market is expected to grow from its current nascent stage to a scale of several billion yuan (approximately several hundred million USD) over the next 3–5 years, but how big it can ultimately become depends on: first, whether universal CAR-T can validate its safety in solid tumors within the next five years; second, whether satricabtagene autoleucel can expand its indications in the two directions of pancreatic cancer and moving up the line to first-line gastric cancer; and third, whether medical insurance payers can, in the near term, give a clear “price-for-volume” signal.
The Distance from “the First” to “Accessible”
The approval of satricabtagene autoleucel is a milestone. It proves that solid tumor CAR-T can move from the laboratory to clinical application, from proof of concept to a real treatment option. For China’s biopharmaceutical industry, this is a rare “global first” — unlike the fast-follow of PD-1, this time a Chinese company truly stands at the technological frontier.
But “reaching the market” does not equal “success.” In the second half of the solid tumor CAR-T game, the core proposition will shift from “can it be made” to “can it be sold” — whether a balance can be found among product pricing, medical insurance negotiation, and patient accessibility; whether the product life cycle can be extended through indication expansion; and whether costs can be continuously driven down through technological iterations such as universal CAR-T.
For CARsgen, every year after 2026 will be a moment of “filling the gap” — get it right, and solid tumor CAR-T becomes a new era of a hundred-billion-yuan market (approximately USD 14 billion); get it wrong, and it is merely another textbook case of technology that wins acclaim but not sales.
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.